Corporations and Health Watch
Tracking the effects of corporate practices on public health
General questions or comments? Email us at response@corporationsandhealth.org
Corporations and Health Watch provides activists, researchers, health professionals, policy makers and others with information and resources so they can act to change corporate practices that harm health.
Click the icons to learn more about each industry.         Receive Our Newsletter  to find out the latest in corporate practices' impact on public health.
Research and Advocacy Forum

The Marin Institute Takes On Big Alcohol and Wins!

Marin Institute Takes on Big Alcohol and Wins In September 2006, San Francisco’s Bay Area Rapid Transit District (BART) board of directors voted to reverse their previous decision prohibiting alcohol advertising on BART buses and trains. Following this announcement, alcohol industry watchdog The Marin Institute took quick action and launched a campaign to get BART to reinstate the ban. The Marin Institute noted that while BART officials pointed to the increased revenues that would be associated with the alcohol ads, they neglected to mention that allowing such ads would further expose young people to alcohol industry marketing.

Two recent studies have noted that alcohol industry advertising has a strong effect on youth and contributes to underage drinking... Read more...

Resources Update

Spotlight on Corporate Practices: The Firearms Industry

As pro-gun legislators, the NRA and the gun industry work to prevent municipal governments from restricting access to handguns, public health advocates will have to find new ways to protect the public from handgun violence.  Read the latest news...

Interview with Lynda Dee, Drug Development Committee member and founder of the AIDS Treatment Activist Coalition (ATAC).

ban abbott In 2003, ATAC joined forces with a coalition of other AIDS treatment advocates, scientists, doctors, and government officials to create the Norvir Pricing Campaign. Abbott Laboratories had announced a more than 500% increase in the price of Norvir, an essential component of combination protease inhibitor therapies for HIV/AIDS. The campaign argued that increasing the price of Norvir, would have a negative impact on AIDS patient care as well as the competitive market for the research and development of new HIV/AIDS therapies. Read the interview...

Check out the archives for previously featured campaigns, research updates, and resources.

About Us | Site Map | Privacy Policy | Contact Us

© 2008 Corporations and Health Watch.
Non-commercial use: The information contained on this website may be reproduced without permission on non-commercial, not-for-profit websites provided that Corporations and Health Watch is explicitly credited and a link is given to our website http://www.corporationsandhealth.org